Nurix Therapeutics (NASDAQ: NRIX) revenue
Nurix Therapeutics reported revenue of $84.0m for fiscal 2025, 54.0% more than in fiscal 2024 ($54.5m). Since fiscal 2019 its revenue has grown by 169.9%, an average growth of 18.0% a year.
Fiscal 2025 is the highest of the 7 fiscal years on record for Nurix Therapeutics. The biggest drop was in fiscal 2020, −42.7%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $84.0m | +54.0% | −$285.7m | −340.2% |
| 2024 | $54.5m | −29.1% | −$213.0m | −390.5% |
| 2023 | $77.0m | +99.3% | −$155.1m | −201.4% |
| 2022 | $38.6m | +29.8% | −$183.9m | −476.0% |
| 2021 | $29.8m | +66.9% | −$117.9m | −396.3% |
| 2020 | $17.8m | −42.7% | −$65.0m | −364.7% |
| 2019 | $31.1m | — | −$22.2m | −71.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Nurix Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Nurix Therapeutics ranks 297th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Nurix Therapeutics, 54.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 295th | 4D Molecular Therapeutics | $85.2m | 230,194.6% |
| 296th | ARS Pharmaceuticals | $84.3m | −5.5% |
| 297th | Nurix Therapeutics | $84.0m | 54.0% |
| 298th | Iradimed | $83.8m | 14.4% |
| 299th | Arcturus Therapeutics | $82.0m | −46.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Nurix Therapeutics
- How much revenue did Nurix Therapeutics make in fiscal 2025?
- Nurix Therapeutics reported revenue of $84.0m for fiscal 2025, compared with $54.5m in fiscal 2024.
- How much has the revenue of Nurix Therapeutics grown?
- Between fiscal 2019 and fiscal 2025 it went from $31.1m to $84.0m: 169.9% more, an average growth of 18.0% a year.
- What was the best year for revenue at Nurix Therapeutics?
- Of its last 7 fiscal years, fiscal 2025, with $84.0m.
- Where does Nurix Therapeutics rank in its sector by revenue?
- It ranks 297th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Nurix Therapeutics come from?
- From the annual report (Form 10-K) that Nurix Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Nurix Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Nurix Therapeutics: the Nurix Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.